Drug makers to face many battles with Dems

For years, the pharmaceutical industry enjoyed the benefits of a Republican-controlled Congress. Figures such as Senator Rick Santorum (R-PA), Billy Tauzin (R-LA) and former CMS administrator Thomas Scully helped create policies and programs that favored the industry. "Now the prospects of the industry's giants have taken a turn. After spending an estimated $10 million on Republican incumbent candidates ahead of this year's mid-term elections--Democrats received about $4.5 million--no other sector is expected to face as hostile a reception on Capitol Hill after the Democrats take over in 2007." A representative for trade organization/lobbying group PhRMA noted that it's time for the industry to woo Democrats, particularly those who are pro-business. And that can't happen a moment too soon. As John Mack of the Pharma Marketing Blog points out, the drug industry is going to face battles on a number of fronts, including the price of prescription drugs, an overhaul of Medicare Part D, greater DTC regulation and increased scrutiny of the FDA.

- read this article from MSNBC
- check out this entry from the Pharma Marketing Blog

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.